RU95104171A - Agent for treatment of immunosuppression at sepsis in human and method of its treatment
- Google Patents
Agent for treatment of immunosuppression at sepsis in human and method of its treatment
Info
Publication number
RU95104171A
RU95104171ARU95104171/14ARU95104171ARU95104171ARU 95104171 ARU95104171 ARU 95104171ARU 95104171/14 ARU95104171/14 ARU 95104171/14ARU 95104171 ARU95104171 ARU 95104171ARU 95104171 ARU95104171 ARU 95104171A
Товарищество с ограниченной ответственностью "Биотех"
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Товарищество с ограниченной ответственностью "Биотех"filedCriticalТоварищество с ограниченной ответственностью "Биотех"
Priority to RU95104171ApriorityCriticalpatent/RU2115428C1/en
Publication of RU95104171ApublicationCriticalpatent/RU95104171A/en
Application grantedgrantedCritical
Publication of RU2115428C1publicationCriticalpatent/RU2115428C1/en
Medicines Containing Material From Animals Or Micro-Organisms
(AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines
(AREA)
Abstract
FIELD: medicine, immunology. SUBSTANCE: method involves the use of the human interleukin-2 by its parenteral administration to patient. Use of the human interleukin-2 ensures to recovery activity and amount of leukocytes and other components of immune system on which active lymphocytes act. EFFECT: enhanced effectiveness of IMMUNOSUPPRESSION treatment.
Claims (1)
В качестве средства для лечения иммуносупрессии при сепсисе у человека предложено применять человеческий интерлейкин-2 (чИЛ-2). Предложен также способ лечения иммуносупрессии при сепсисе путем парентерального введения пациенту чИЛ-2. Использование чИЛ-2 позволяет восстановить активность и количество лейкоцитов, а также остальных компонентов иммунной системы, на которые воздействуют активные лимфоциты, и тем самым обеспечить эффективное лечение иммуносупрессии.It has been proposed to use human interleukin-2 (hIL-2) as an agent for the treatment of immunosuppression in sepsis in humans. A method for the treatment of immunosuppression in sepsis by parenteral administration of hIL-2 to a patient is also proposed. Using chIL-2 allows you to restore the activity and number of leukocytes, as well as other components of the immune system that are affected by active lymphocytes, and thereby provide effective treatment for immunosuppression.
RU95104171A1995-03-281995-03-28Method of treatment of human with immunosuppression at sepsis
RU2115428C1
(en)
Therapeutic application of chimeric and radiolabeled antibodies to human b lymphocyte restricted differentiation antigen for treatment of b cell lymphoma
Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
Use of material obtained from mycobacterium vaccae for production of therapeutic agent used for psychiatric disease treatment, method of psychiatric disease treatment, product containing antigenic and/or immunoregulating material, pharmaceutical agent